Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe short answer: the thigh and the abdomen are both licensed injection sites for Wegovy, and clinical evidence does not show that one site produces meaningfully greater weight loss than the other. What matters most is rotating between sites, injecting correctly, and staying consistent week to week. That said, the two sites do behave differently in practice, and knowing why can help you choose. These are prescription-only medicines assessed and supervised by a qualified prescriber, so any questions about what suits your individual situation should go to your clinical team. The sections below walk through the real factors behind the decision.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A common misconception is that injecting into the stomach gets the medicine into your bloodstream faster, and that faster absorption means it works harder. It is a reasonable thought, but it is not quite how semaglutide works. Wegovy is a once-weekly injection: its effect builds gradually over the full seven days, not in the hour after you inject. Small differences in how quickly the abdomen versus the thigh absorbs the medicine do not translate into a measurable difference in how much weight you lose over weeks and months.
What does matter is the quality of the injection, reaching the subcutaneous fat layer consistently, not injecting into muscle or skin. That is true regardless of which site you use. The Wegovy overview on our site covers the broader picture of how semaglutide works as a GLP-1 receptor agonist and what drives its effects on appetite and body weight.
Comfort and confidence also matter. If you are tense about injecting into your abdomen, a tense muscle or flinch can change the injection angle. A site you use calmly and confidently is likely to give a more consistent result than the site that anxiety says is theoretically superior. It is also worth knowing that whether you take Wegovy on an empty stomach or not is a separate but related question that many people have when they are thinking about how to get the most from each dose.
The abdomen offers a large, accessible area with typically good subcutaneous fat coverage, which is why it is the site many people start with. Injecting into the abdomen also allows you to see what you are doing easily, useful in the early weeks when you are building confidence. For more on technique and what to expect from abdominal injections, our guide to Wegovy in the stomach goes into detail on positioning and common questions.
The thigh (specifically the front and outer part, mid-thigh) is a good alternative if your abdomen is tender, has scar tissue, or if you have recently injected there. The thigh can be easier to reach if you have limited dexterity in one hand, and sitting down while injecting can stabilise the leg. Our page on injecting Wegovy in the thigh covers positioning and what to watch for at this site.
The upper arm is the third licensed site but typically requires a second person's help or a stabilising technique, so most self-injectors treat it as a rotation option rather than their primary site.
Rotation is the factor that has the clearest practical impact on long-term injection quality. Using the same small patch of skin week after week can cause lipohypertrophy, a firm, fatty lump under the skin that absorbs medicine unpredictably. This is well-documented with injectable medicines generally, and the NHS semaglutide page advises changing the site with each dose.
A simple rotation pattern: abdomen left side one week, abdomen right side the next, front-left thigh the week after, front-right thigh the week after that. Some people include the upper arm when they have help. The key is spacing injections at least a few centimetres from any spot used in the past two or three weeks. If you notice a hard or lumpy area at your usual site, avoid it and speak to your prescriber.
For a full comparison of site options side by side, the Wegovy stomach or thigh page sets out the practical trade-offs clearly.
For most people this is genuinely a matter of comfort and rotation logistics. But a few situations make site choice more clinically relevant. If you also inject insulin or another subcutaneous medicine, your prescriber will want to ensure different medicines go into different sites and are kept apart by a safe distance. If you have had abdominal surgery, significant scar tissue, or a hernia, the abdomen may not be the best primary site. And if skin reactions keep recurring at one site despite good rotation, your clinical team may suggest a change.
Questions about whether Wegovy is the right choice for you, or how it compares with other licensed options, are worth exploring properly. You can read about semaglutide in more detail or look at our weight-loss treatment overview to understand the full picture. If you are ready to talk to a prescriber about your own situation, you can start a free consultation with our clinical team, a GPhC-registered prescriber reads every submission and responds the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.